Novo stops development activities in inflammatory disorders

After reviewing its strategic position in the inflammatory diseases space after discontinuing anti-IL-20 for the treatment of rheumatoid arthritis, Novo Nordisk (NYSE:NVO) decides to discontinue its R&D efforts in the area. EVP and CSO Mads Krogsgaard Thomsen says, "The discontinuation of anti-IL-20 delays our earliest possible entrance into the market for anti-inflammatory therapeutics to the late 2020s. Significant unmet opportunities remain within diabetes, including prevention, obesity and diabetes complications. We have therefore decided to further increase our R&D efforts within diabetes which is our main business area."

The company's decision will affect ~400 employees. Management believes it will be possible to offer ~200 other jobs within the organization.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs